Qube Research & Technologies (QRT)
CRNX

Qube Research & Technologies (QRT)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,402
Closed -$269K – 3555
2026
Q1 		$269K Buy
+7,402
New +$331K ﹤0.01% 2891
2025
Q3 		– Sell
-198,917
Closed -$5.72M – 3634
2025
Q2 		$5.72M Sell
198,917
-230,146
-54% -$7.11M 0.01% 1622
2025
Q1 		$14.4M Buy
429,063
+209,539
+95% +$7.83M 0.02% 915
2024
Q4 		$11.2M Sell
219,524
-68,270
-24% -$3.82M 0.01% 1025
2024
Q3 		$14.7M Sell
287,794
-103,147
-26% -$5.32M 0.02% 811
2024
Q2 		$17.5M Buy
390,941
+296,074
+312% +$13.7M 0.03% 659
2024
Q1 		$4.44M Buy
94,867
+37,152
+64% +$1.45M 0.01% 1300
2023
Q4 		$2.05M Buy
+57,715
New +$1.77M ﹤0.01% 1505
2023
Q3 		– Sell
-55,798
Closed -$1.01M – 4122
2023
Q2 		$1.01M Buy
55,798
+44,763
+406% +$893K ﹤0.01% 1293
2023
Q1 		$177K Buy
+11,035
New +$204K ﹤0.01% 1972
2022
Q3 		– Sell
-10,798
Closed -$201K – 2572
2022
Q2 		$201K Buy
+10,798
New +$215K ﹤0.01% 1736

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CRNX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 7,402 shares — an estimated $269K sold.

Qube Research & Technologies (QRT) first reported a position in CRNX in Q2 2022 and held it in 11 quarters. The position peaked at $17.5M in Q2 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 7,402 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $269K.
  • Qube Research & Technologies (QRT) first reported a position in Crinetics Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Qube Research & Technologies (QRT)'s Crinetics Pharmaceuticals position peaked at $17.5M in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.